First targeted therapy for children with achondroplasia shows persistent height gain
2021-03-20
(Press-News.org) WASHINGTON--Children with achondroplasia, the most common form of disproportionate short stature, grow taller with trends in improved body proportions after two years of daily vosoritide treatment, a new study analysis finds. Results of the industry-sponsored study will be presented at ENDO 2021, the Endocrine Society's annual meeting.
"This is the first robust evidence of a precision therapy for achondroplasia," said the lead investigator, Ravi Savarirayan, M.D., Ph.D., a professor at Murdoch Children's Research Institute at Royal Children's Hospital in Parkville, Australia.
Achondroplasia is a genetic bone growth disorder whose characteristics include short arms and legs and an adult height typically below 4 feet, 6 inches. Medical complications of achondroplasia include spinal stenosis (narrowing of the spinal column) and spinal cord compression, bowed legs, permanently swayed lower back and sleep apnea. Treatment focuses on relieving symptoms and is often surgical. There is currently no effective treatment to increase height in these patients.
Vosoritide is an investigational drug targeting the overactive signal in the growth plate that prevents bone growth in children with achondroplasia, Savarirayan said. The goal of treatment, he added, is better medical, functional and psychosocial outcomes.
"We hope that improved height and body proportion will increase independence and alleviate some of the long-term issues, such as spinal stenosis," Savarirayan said.
A prior study in children ages 5 to 17 with achondroplasia showed that one year of daily injections of vosoritide significantly improved the participants' annualized growth velocity (AGV), which is the annual height gain, compared with a placebo, or dummy drug. The new study extends the data analysis after an additional year of continuous vosoritide treatment.
In the extension study, 61 children who had received the placebo the first year switched to vosoritide therapy, and 58 children continued vosoritide treatment for another 52 weeks. Final follow-up data were available for 108 of the 119 children.
Children who received two years' vosoritide therapy had a baseline mean AGV of 4.28 cm/year. After one year of treatment, mean AGV was 5.71 cm/year and after the second year mean AGV was 5.65 cm/year. After the second year of treatment, they also had a better height z-score, which is a measure of height relative to that of a similar population of average height.
Additionally, the children showed trends towards a better ratio of upper to lower body segments. Savarirayan said an improved body proportion often means the children can now more easily reach objects and perform self-care, such as toileting. Longer term follow-up is ongoing where additional data on quality of life, functional measures and final adult height will help to confirm the clinical relevance of these improvements in growth and proportionality.
These findings, Savarirayan said, indicate that vosoritide has persistent two-year beneficial effects on growth in children with achondroplasia.
Furthermore, the data showed that in children who received one year of vosoritide therapy after stopping placebo, growth also improved.
Vosoritide is under study in children whose growth plates are still open. They can receive the drug until they are near final adult height, which is 16 to 18 years old, according to Savarirayan. While these data are encouraging at showing a durable treatment effect up to 2 years, the long-term clinical benefits of vosoritide will likely require many more years of evaluation, and we will continue to investigate these important questions as part of the long-term follow-up portion of this study, he said.
Achondroplasia occurs in one in every 15,000 to 35,000 births, according to the National Organization for Rare Disorders.
INFORMATION:
BioMarin, the drug maker, funded this study. The investigators conducted the study and analyzed the data independent of the manufacturer.
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at http://www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
ELSE PRESS RELEASES FROM THIS DATE:
2021-03-20
WASHINGTON--A study in mice finds treatment with a molecule called MCB-613 repairs heart tissue after a severe heart attack, preventing damage that can lead to heart failure. The findings are being presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
"This is a remarkable discovery that may lead to effective and safe treatments to prevent the progression to heart failure after a heart attack," said lead researcher Lisa K. Mullany, Ph.D., of Baylor College of Medicine in Houston.
Heart failure after a heart attack is the leading cause of death in humans, and currently there are no definitive therapies other than heart transplantation.
Researchers had previously found that MCB-613 stimulates proteins called steroid receptor coactivators ...
2021-03-20
WASHINGTON--Children with adrenal insufficiency--a condition in which the adrenal gland does not function properly--are at more than 10 times higher risk for COVID-19 complications and death compared with children with normal adrenal glands, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
Adrenal insufficiency is a disorder that occurs when the adrenal glands, located just above the kidneys, don't make enough of the hormone cortisol. The primary form of adrenal insufficiency is also called Addison's disease. Known as the "stress ...
2021-03-20
WASHINGTON--Blood glucose levels improved among children and teens with type 1 diabetes during the first 12 weeks of COVID-19 lockdown in the United Kingdom, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
"The findings demonstrate the difficulties faced by patients and families managing type 1 diabetes around school pressures, meals away from home, social life and peer pressure," said lead researcher Neil Lawrence, M.B.Ch.B., of Sheffield Children's Hospital NHS Foundation Trust in Sheffield, United Kingdom. "Children and families found it easier to manage this disease when they were ...
2021-03-20
WASHINGTON--The chemicals present in white button mushrooms may slow the progression of prostate cancer, according to a mouse study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
"Androgens, a type of male sex hormone, promote the growth of prostate cancer cells by binding to and activating the androgen receptor, a protein that is expressed in prostate cells," said lead researcher Xiaoqiang Wang, M.D., Ph.D., M.B. (A.S.C.P.), of the Beckman Research Institute of City of Hope, a comprehensive cancer center in Duarte, Calif. "White button mushrooms appear to suppress the activity of the androgen receptor."
City of Hope's Shiuan ...
2021-03-20
WASHINGTON--Women with obesity and polycystic ovarian syndrome (PCOS) are at increased risk of developing type 2 diabetes, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting. Normal-weight women with PCOS are not at increased risk, the researchers found.
Women with PCOS had a more than three-fold increased risk of developing type 2 diabetes during their lifetime, the study found. This risk was evident only in women who met the criteria for overweight or obesity, but not in lean women.
"We strongly suggest weight management in women with obesity and PCOS in an attempt to reduce this major risk of ...
2021-03-20
WASHINGTON--Only 3% of patients at high risk for primary aldosteronism (PA), a common disorder that causes high blood pressure and can lead to heart and kidney complications, are screened for the condition, according to a study that will be presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
"The results of our study indicate that initiatives to encourage PA screening are crucial for preventing cardiovascular and kidney disease in many patients with hypertension," said lead researcher Seda Grigoryan, M.D., of Michigan State University in Lansing, Mich.
PA is the most common form of secondary hypertension--high blood pressure caused by another disease. END ...
2021-03-20
WASHINGTON--A lifestyle intervention targeting women with obesity and infertility is more effective in increasing the pregnancy rate compared with fertility treatments, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
The lifestyle intervention, called the Fit-For-Fertility (FFF) program, is a cost-effective alternative to the usual standard of care for women with obesity seeking fertility treatments, according to lead researcher Matea Belan, Ph.D., of the University of Sherbrooke and the Research Center of the Centre Hospitalier Universitaire de Sherbrooke (RC-CHUS) in Quebec, Canada. "Our study shows that the FFF program can significantly improve the pregnancy rate, especially the spontaneous pregnancy ...
2021-03-20
WASHINGTON--Transgender youth have higher odds than cisgender youth of being diagnosed with medical conditions that can affect their overall metabolic and cardiovascular health, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
The study included 4,174 youth with a diagnosis of gender dysphoria, a term for a deep sense of unease and distress that may occur when a person's gender identity does not match their sex designated at birth. An estimated 1.8% of adolescents identify as transgender, according to lead researcher Anna Valentine, M.D., of the University of Colorado Anschutz Medical ...
2021-03-20
WASHINGTON--Patients with low vitamin D levels who are hospitalized for COVID-19 may have a lower risk of dying or requiring mechanical ventilation if they receive vitamin D supplementation of at least 1,000 units weekly, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
"Given how common vitamin D deficiency is in the world and the United States, we believe that this research is highly relevant right now," said co-author Sweta Chekuri, M.D., of Montefiore Health System and Albert Einstein College of Medicine in the Bronx, New York.
Research has shown that vitamin D supplementation can prevent inflammation in other respiratory diseases, but there have been limited studies examining the role of vitamin D supplementation in COVID-19. ...
2021-03-20
WASHINGTON--Black women with polycystic ovary syndrome (PCOS) have higher risk factors for heart disease, diabetes and stroke compared with white women, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
PCOS is a common disorder characterized by irregular menstrual periods, disruption of normal metabolism and excessive hair growth. PCOS affects up to 10% of all women of reproductive age. The disorder increases the risk for health conditions including infertility, obesity, heart disease, type 2 diabetes, depression and certain ...
LAST 30 PRESS RELEASES:
[Press-News.org] First targeted therapy for children with achondroplasia shows persistent height gain
